Skip to main content
Explore URMC

menu

Ovarian Cancer: Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Research Question:
Does niraparib, in combination with with bevacizumab, help delay the worsening of cancer in people who had a good response to earlier treatment in with a platinum-type chemotherapy drug?

Basic Study Information

Purpose:
It is not known how long your participation the study will last. You may receive Niraparib for up to 3 years and Bevacizumab for up to 15 months. The number of months that you receive bevacizumab on the study depends on how many months of bevacizumab you received with chemotherapy before this study.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03326193?term=3000-02-004&rank=1
Study Reference #: IGYO18026

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Moore

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu

Additional Study Details

Return to Search